Medicine recalls
|
| |
| The United Kingdom: Company led medicines recall: Mawdsley-Brooks & Company Limited, Fluphenazin-neuraxpharm® D 25 & 100 mg/ml Solution for Injection |
| |
Medicines and Healthcare products Regulatory Agency (MHRA) announces that specific batches of the following fluphenazine products are recalled as a precautionary measure due to validation tests demonstrating the leaching of filter additives that are above the acceptable limit:
- Fluphenazin-neuraxpharm® D 25 mg/ml Solution for Injection (batch number: 202052)
- Fluphenazin-neuraxpharm® D 100 mg/ml Solution for Injection (batch number: 200686)
Please refer to the following website in MHRA for details:
http://www.gov.uk/drug-device-alerts/company-led-medicines-recall-mawdsley-brooks-and-company-limited-fluphenazin-neuraxpharm-r-d-25-and-100-mg-slash-ml-solution-for-injection-clmr-23-a-slash-01
In Hong Kong, Fluphenazin-neuraxpharm D Solution For Injection 25mg/ml (HK-64620) is a pharmaceutical product registered by Hind Wing Co Ltd (Hind Wing). The product is a prescription-only medicine.
On 1 Dec 2022, the Department of Health endorsed Hind Wing to recall one batch of Fluphenazin-neuraxpharm D Solution For Injection 25mg/ml (HK-64620) (batch number: 202052) due to potential quality issue. A recall statement was posted on the Drug Office website on the same date.
Related news was previously issued by Singapore Health Sciences Authority, and was posted on the Drug Office website on 13 Dec 2022.
Fluphenazin-neuraxpharm® D 100 mg/ml Solution for Injection is not a registered pharmaceutical product.
Ends/Friday, Jan 13, 2023
Issued at HKT 15:00
|
| |
|
